

Cyltezo[®] (adalimumab-adbm) – Correction - high concentration formulation approved as biosimilar, not interchangeable

- On May 1, 2024, <u>Boehringer Ingelheim announced</u> the FDA approval of <u>Cyltezo (adalimumab-adbm)</u> citrate-free, high concentration (40 mg/0.4 mL) injection, biosimilar to AbbVie's <u>Humira[®]</u> (adalimumab).
 - Cyltezo was previously launched as biosimilar and *interchangeable* to Humira in the low concentration strengths (40 mg/0.8 mL, 20 mg/0.4 mL, and 10 mg/0.2 mL).
 - There are five other high concentration biosimilar formulations approved for Humira: <u>Amjevita[™]</u> (adalimumab-atto), <u>Hyrimoz[®]</u> (adalimumab-adaz), <u>Hadlima[™]</u> (adalimumab-<u>bwwd</u>), <u>Simlandi[®]</u> (adalimumab-ryyk), and <u>Yuflyma[®]</u> (adalimumab-aaty).
 - Hyrimoz (80 mg/0.8 mL, 20 mg/0.2 mL, 10 mg/0.1 mL) and Simlandi (40 mg/0.4 mL) have been granted <u>interchangeability</u>.
- Cyltezo high-concentration formulation is priced at a 5% discount to Humira under the brand name Cyltezo and at an 81% discount to Humira as the unbranded product adalimumab-adbm.
- Cyltezo high concentration formulation is available as a 40 mg/0.4 mL single-dose pen and singledose prefilled syringe.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.